Acalabrutinib
Overview | |
Catalog # | bs-6468c-2mg-solid |
Product Name | Acalabrutinib |
Specifications | |
Storage Buffer | Powder |
Storage Condition | Store in dry, dark place at -20C for 1 year. |
Target | |
Product Information | Molecular Weight: 465.51 Formula: C26 H23 N7 O2 CAS Number: 1420477-60-6 InChi Key: WDENQIQQYWYTPO-IBGZPJMESA-N InChi: InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1 Smiles: CC#CC(=O)N1CCC[C@H]1C1=NC(C2C=CC(=CC=2)C(=O)NC2C=CC=CN=2)=C2C(N)=NC=CN12 Purity: 98.0 Solubility: Soluble in DMSO, not in water Appearance: Solid Power Shelf Life: 1.0 years |
Description | Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival. |